Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
SUCLA2 CRISPR/Cas9 KO Plasmid (m): sc-423214
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SUCLA2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the SUCLA2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: SUCLA2 Antibody (A-9): sc-374107
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SUCLA2 CRISPR/Cas9 KO Plasmid (m) | sc-423214 | 20 µg | $397.00 |
Overview
Sucla2 encodes the mouse SUCLA2 beta subunit of succinyl-CoA synthetase (ADP-forming), a mitochondrial matrix enzyme that catalyzes the reversible conversion of succinyl-CoA to succinate with ATP generation in the tricarboxylic acid (TCA) cycle. Through this reaction, SUCLA2 supports oxidative metabolism, anaplerotic flux, and coordination between the TCA cycle and heme/ketone body–related succinyl-CoA utilization. SUCLA2 function is closely linked to mitochondrial energy homeostasis and nucleotide balance, and perturbation of this pathway is associated with mitochondrial encephalomyopathy phenotypes and mtDNA maintenance defects reported for SUCLA2-related mitochondrial disorders. In mouse models, Sucla2 is therefore relevant for studying metabolic stress responses, neuromuscular vulnerability, and mechanisms connecting TCA cycle enzymes to mitochondrial genome stability.
SUCLA2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Sucla2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Sucla2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Sucla2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SUCLA2 protein expression.
This CRISPR knockout system enables efficient generation of Sucla2-deficient cell models for investigation of SUCLA2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Sucla2 exon(s) critical for SUCLA2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Sucla2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by SUCLA2 CRISPR/Cas9 KO Plasmid (m) and SUCLA2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Sucla2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by SUCLA2 HDR Plasmid (m) and SUCLA2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Sucla2 homology arms to support homology-directed repair at defined Sucla2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.